Goldman Sachs Group Inc Profound Medical Corp. Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.3 - $9.46 $40,150 - $52,030	-5,500 Reduced 24.77%	16,700 $142,000
Q4 2023 Feb 13, 2024	BUY	$7.85 - $11.18 $21,980 - $31,304	2,800 Added 14.43%	22,200 $188,000
Q3 2023 May 14, 2024	SELL	$7.91 - $13.27 $22,148 - $37,156	-2,800 Reduced 12.61%	19,400 $197,000
Q3 2023 Nov 14, 2023	BUY	$7.91 - $13.27 $21,357 - $35,829	2,700 Added 16.17%	19,400 $197,000
Q2 2023 May 14, 2024	SELL	$9.27 - $14.88 $50,985 - $81,840	-5,500 Reduced 24.77%	16,700 $217,000
Q2 2023 Aug 14, 2023	BUY	$9.27 - $14.88 $154,809 - $248,496	16,700 New	16,700 $217,000

8.93M

1.2K

Ticker PROF
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,851,300
Market Cap $157M
Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.